Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583206 | 0.84 | HTT (0.44) | MAPTALDH1A1LMNAGPR174SMN1; SMN2 | |
| SCHEMBL5215471 | 0.83 | SCN9A (0.44) | DPP4GPR119SCN9AMAPTALDH1A1 | |
| SCHEMBL7254865 | 0.83 | DPP4 (0.53) | DPP4GPR119SCN9AMAPTKDM4E | |
| SCHEMBL31043946 | 0.82 | LMNA (0.52) | DPP4GPR119SCN9AMAPTALDH1A1 | |
| SCHEMBL5222332 | 0.82 | GPR119 (0.43) | DPP4GPR119SCN9AMAPTALDH1A1 | |
| SCHEMBL5216291 | 0.81 | SMN1; SMN2 (0.45) | GPR119MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL1872135 | 0.78 | DPP4 (0.58) | DPP4GPR119SCN9AMAPTKDM4E | |
| SCHEMBL4239855 | 0.77 | DPP4 (0.54) | DPP4GPR119KDM4EPKMTLR7 | |
| SCHEMBL8221482 | 0.76 | MAPT (0.60) | MAPTALDH1A1LMNAGPR174SMN1; SMN2 | |
| SCHEMBL20971728 | 0.76 | DPP4 (0.53) | DPP4GPR119SCN9AKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | DPP4 2277/4885GPR119 1394/4885SCN9A 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.